Insider Selling: Phreesia (NYSE:PHR) SVP Sells $41,019.36 in Stock

Key Points

• Amy Beth Vanduyn, SVP of Phreesia, sold 1,762 shares of the company's stock for a total of $41,019.36, resulting in a 1.54% decrease in her holdings.
• Phreesia recently reported quarterly earnings of $0.01 per share, beating expectations and showing a 14.9% revenue increase year-over-year.
• Analysts are generally optimistic, with a consensus rating of "Buy" and an average price target of $34.08 for Phreesia's stock.

Phreesia, Inc. (NYSE:PHR - Get Free Report) SVP Amy Beth Vanduyn sold 1,762 shares of the company's stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $41,019.36. Following the transaction, the senior vice president owned 112,479 shares in the company, valued at $2,618,511.12. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Amy Beth Vanduyn also recently made the following trade(s):

• On Thursday, July 17th, Amy Beth Vanduyn sold 640 shares of Phreesia stock. The stock was sold at an average price of $26.89, for a total value of $17,209.60.

Phreesia Stock Performance

PHR traded up $1.00 during trading on Thursday, hitting $24.28. 801,987 shares of the company's stock were exchanged, compared to its average volume of 1,182,744. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $32.76. The business's 50 day moving average is $27.71 and its two-hundred day moving average is $26.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. The business had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The firm's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. As a group, analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Phreesia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in Phreesia by 2.4% during the first quarter. Vanguard Group Inc. now owns 4,936,515 shares of the company's stock worth $126,177,000 after purchasing an additional 113,405 shares during the period. Greenhouse Funds LLLP lifted its stake in shares of Phreesia by 12.5% during the 2nd quarter. Greenhouse Funds LLLP now owns 3,325,262 shares of the company's stock valued at $94,637,000 after buying an additional 368,352 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in Phreesia by 20.0% in the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company's stock worth $75,312,000 after buying an additional 490,340 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Phreesia by 108.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company's stock worth $67,606,000 after buying an additional 1,377,904 shares during the period. Finally, Franklin Resources Inc. grew its stake in Phreesia by 0.6% in the 2nd quarter. Franklin Resources Inc. now owns 1,524,251 shares of the company's stock valued at $43,380,000 after buying an additional 9,057 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on PHR shares. KeyCorp upped their target price on shares of Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. Piper Sandler upped their price objective on shares of Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a research report on Friday, September 5th. Citigroup reissued an "outperform" rating on shares of Phreesia in a research report on Monday, September 8th. JMP Securities upped their target price on Phreesia from $30.00 to $34.00 and gave the company a "market outperform" rating in a report on Monday, September 8th. Finally, Stephens reiterated an "overweight" rating and set a $32.00 price target on shares of Phreesia in a report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $34.08.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.